Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Strides Arcolab Ltd Announces US FDA Approval For Its Italian Semi-Solids And Oinment Facility


Wednesday, 18 Sep 2013 05:40am EDT 

Strides Arcolab Ltd announced that it has received US FDA approval for Beltapharm's facility at Milan, Itlay. This EU and TGA (Australia) approved facility located in Milan, Itlay, manufactures liquids, semi-solids, ointments and creams. The Company is expecting its first approval of a niche semisolids product by first quarter of 2014. 

Company Quote

912.0
13.85 +1.54%
2:09am EST